867 Anti-MAdCAM Monoclonal Antibody PF-00547659 Does Not Affect Immune Surveillance in the Central Nervous System of Crohn's Disease Patients Who Are Anti-TNF Inadequate Responders: Results From the Tosca Study
Walter Reinisch(Medical University of Vienna), Geert D’Haens(Amsterdam University Medical Centers), Séverine Vermeire(KU Leuven), Andre M. Van Gossum, William J. Sandborn(University of San Diego), Richard M. Ransohoff(Cleveland Clinic Lerner College of Medicine), Olaf Stüve(Southwestern Medical Center), Fabio Cataldi(Pfizer (United States)), Gail M. Comer(Pfizer (United States)), Daniel C. Baumgart(University of Alberta), Matthieu Allez(Inserm), Mina Hassan‐Zahraee(Pfizer (United States)), Bo Jin(Radboud University Nijmegen), Sunday Rivers(Pfizer (United States)), Annamarie Kaminski(Pfizer (United States)), Pierre Desreumaux(Active Biotech (Sweden)), John B. Cheng(Pfizer (United States)), Vivek Pradhan(Pfizer (United States)), Kenneth J. Gorelick, Yanhua Zhang, Harald Vogelsang(Medical University of Vienna)
Cited by 1
Related Papers
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Crohn's disease
|The Lancet|2012|2.1k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k